Organization
University of Ulm
11 clinical trials
3 abstracts
Abstract
Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer: A subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.Org: University Hospital of Schleswig Holstein, Klinikum Esslingen, University Hospital Rostock, Karolinska Institutet, Capio St. Göran’s Hospital,
Abstract
MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET).Org: University Hospital Schleswig-Holstein Campus Lübeck, Breast Cancer Center, Affiliated Cancer Hospital of Chongqing University, Chongqing, China, Die Filderklinik, University of Ulm, Aberdeen Breast Unit,
Clinical trial
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)Status: Completed, Estimated PCD: 2024-02-01
Clinical trial
Course of Inflammation and Infection Markers in Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab ApplicationStatus: Completed, Estimated PCD: 2022-04-28
Clinical trial
Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse GeneticsStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's MacroglobulinemiaStatus: Completed, Estimated PCD: 2018-11-01
Clinical trial
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaStatus: Not yet recruiting, Estimated PCD: 2027-10-01
Clinical trial
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MyelofibrosisStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene MutationStatus: Completed, Estimated PCD: 2021-09-01
Clinical trial
Pembrolizumab in Marginalzone Lymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDYStatus: Recruiting, Estimated PCD: 2029-04-01
Abstract
Patient perspectives on CLL treatment side effects: A sub-analysis of the VOICE survey.Org: Alfred Health, H. Lee Moffitt Cancer Center and Research Institute, Antalya Research and Training Hospital, Fundaleu, University Hospital Hradec Králové,